Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Saved in:
| Title: | Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. |
|---|---|
| Authors: | Bahlis, Nizar J.1 (AUTHOR), Siegel, David S.2 (AUTHOR), Schiller, Gary J.3 (AUTHOR), Samaras, Christy4 (AUTHOR), Sebag, Michael5 (AUTHOR), Berdeja, Jesus6 (AUTHOR), Ganguly, Siddhartha7 (AUTHOR), Matous, Jeffrey8 (AUTHOR), Song, Kevin9 (AUTHOR), Seet, Christopher S.3 (AUTHOR), Acosta-Rivera, Mirelis10 (AUTHOR), Bar, Michael11 (AUTHOR), Quick, Donald12 (AUTHOR), Anz, Bertrand13 (AUTHOR), Fonseca, Gustavo14 (AUTHOR), Chung, Weiyuan15 (AUTHOR), Lee, Kim15 (AUTHOR), Mouro, Jorge16 (AUTHOR), Agarwal, Amit15 (AUTHOR), Reece, Donna17 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Jun2022, Vol. 63 Issue 6, p1407-1417. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
